Monument Therapeutics

Monument Therapeutics is a clinical-stage biotechnology company applying precision medicine to CNS drug development.

The company uses proprietary digital biomarkers to stratify patients by shared neurobiological profiles, matching them to targeted small molecule treatments. Its pipeline addresses conditions of high unmet need, including cognitive impairment associated with schizophrenia and neuroinflammation.

By combining patient stratification with novel reformulations of well-characterised CNS-active compounds, Monument aims to improve clinical trial success rates in psychiatry and neurology.